Drug intelligence / Profile preview

NTS04a

Development stage: Preclinical
Lead developer: NTC Pharma

Overview

**NTS04a** is an NTC clinical-development asset listed in the company's pipeline for post-operative bowel preparation and an indication recorded as SAID. Publicly available NTC pipeline information does not disclose its active ingredient, modality, molecular target, mechanism of action, formulation, route of administration, or a more specific clinical phase.

Beyond the preview

Go deeper on NTS04a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTS04a.

Explore the full profile